Zegenex develops medicated wound‑healing devices designed to accelerate recovery and minimize scarring for injuries such as lacerations, burns, and diabetic foot ulcers. Their patented technology, licensed from the University of Pittsburgh, combines advanced drug delivery with proprietary biomaterials, and preclinical studies have shown significant reductions in scar formation and faster tissue regeneration. The platform targets clinicians and healthcare systems seeking faster patient outcomes and lower complication rates.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic and acute wounds such as lacerations, burns, and diabetic foot ulcers often heal slowly, leading to prolonged treatment, increased risk of infection, and significant scarring. Existing dressings provide limited bioactive support, leaving clinicians without effective options to accelerate tissue regeneration and improve patient outcomes.
Solution
Zegenex offers medicated wound‑healing devices that incorporate a patented, university‑licensed platform designed to promote rapid tissue regeneration and reduce scar formation. The devices deliver a controlled release of therapeutic agents directly to the wound site, enhancing cellular repair processes demonstrated in preclinical studies. By integrating this technology into standard wound‑care protocols, clinicians can achieve faster closure times and better cosmetic results, ultimately shortening treatment courses and lowering complication rates. The platform is protected by a U.S. full patent, ensuring exclusive use of the underlying formulation and delivery system.
Target Audience
Primary customers are wound‑care specialists, surgeons, and clinicians managing acute injuries and chronic ulcers, particularly in hospital wound‑care units and outpatient clinics.
Features
- Patented drug‑delivery matrix that provides sustained, localized release of regenerative compounds
- Formulated to target key pathways in tissue repair, accelerating epithelialization and collagen remodeling
- Preclinical evidence showing reduced scar tissue and faster wound closure across multiple injury models
- Compatible with standard dressing application techniques for easy integration into existing clinical workflows
- Scalable manufacturing process that supports a range of wound sizes and types